Abstract
Granulocyte Colony Stimulating Factors (G-CSF) are recommended by cancer consortia for the management of febrile neutropenia. Also recommended are viable alternatives, of which chemotherapy dose reduction (CDR) is well suited, as it may lead to cost savings for patients and payers. Evidence is lacking on the value of G-CSF in metastatic tumors. This study aimed to compare survival outcomes among 1) G-CSF treated vs G-CSF untreated patients and 2) G-CSF treated vs CDR treated patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
